Perspective Therapeutics (CATX) Change in Accured Expenses (2010 - 2026)

Perspective Therapeutics has disclosed Change in Accured Expenses across 17 years of filings, most recently posting -$4.2 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$4.2 million, down 64.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.5 million (down 824.64% YoY), and the FY2025 annual result was $147000.0, down 92.22% from the prior year.
• Change in Accured Expenses came in at -$4.2 million for Q1 2026 at Perspective Therapeutics, down from -$1.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $15.7 million in Q3 2024 to a low of -$13.0 million in Q4 2024.
• The 5-year median for Change in Accured Expenses is $117000.0 (2022), against an average of $90647.1.
• Across the five-year window, Change in Accured Expenses jumped 3725.0% in 2022 and sank 678.32% in 2024, its largest moves.
• Perspective Therapeutics' Change in Accured Expenses stood at $573000.0 in 2022, then surged by 293.72% to $2.3 million in 2023, then tumbled by 678.32% to -$13.0 million in 2024, then surged by 91.68% to -$1.1 million in 2025, then slumped by 287.94% to -$4.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$4.2 million (Q1 2026), -$1.1 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.